S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
S&P 500   4,164.00
DOW   34,156.69
QQQ   309.88
Two Billionaires Are Rigging the Market. Here’s How to Fight Back
The #1 Energy Stock to Buy (Ad)
3 Hot Stocks The Analysts Are Buying 
Is Biotech Immunocore About To Make A 25% Price Move?
The #1 Energy Stock to Buy (Ad)
Why Is Wall Street Loving Amazon So Much? 
Want to Invest in ChatGPT? Then Buy Microsoft Stock
The #1 Energy Stock to Buy (Ad)
Stocks end higher after zig-zagging on Fed chair's comments
Patient Clorox Shareholders Are Cleaning Up
NASDAQ:SYNH

Syneos Health - SYNH Stock Forecast, Price & News

$38.22
+0.64 (+1.70%)
(As of 02/7/2023 12:00 AM ET)
Add
Compare
Today's Range
$37.13
$38.37
50-Day Range
$33.96
$38.22
52-Week Range
$22.89
$92.57
Volume
608,151 shs
Average Volume
1.65 million shs
Market Capitalization
$3.93 billion
P/E Ratio
13.90
Dividend Yield
N/A
Price Target
$53.60

Syneos Health MarketRank™ Forecast

Analyst Rating
Hold
2.10 Rating Score
Upside/​Downside
40.2% Upside
$53.60 Price Target
Short Interest
Bearish
7.10% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.00
Upright™ Environmental Score
News Sentiment
1.00mentions of Syneos Health in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-23.35%
From $4.24 to $3.25 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.16 out of 5 stars

Medical Sector

388th out of 1,029 stocks

Commercial Physical Research Industry

7th out of 16 stocks

SYNH stock logo

About Syneos Health (NASDAQ:SYNH) Stock

Syneos Health, Inc. engages in the provision of outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded in 1998 and is headquartered in Morrisville, NC.

Receive SYNH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syneos Health and its competitors with MarketBeat's FREE daily newsletter.

SYNH Stock News Headlines

The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Syneos Health (SYNH) Signs New Partnership With Cryoport
Cryoport Announces Strategic Partnership With Syneos Health
The #1 Energy Stock to Buy
The next major energy revolution is unfolding right now. And it could hand early investors as much as 46,700% gains…
Syneos Health CFO Meggs to leave company
2023 Faces to Watch: Syneos Health CEO Michelle Keefe
Syneos Health Extends Partnership with Medable
Tetris Pharma signs service agreement with Syneos Health
Syneos Health Releases 2023 Health Trends
Is Investing in Syneos Health (SYNH) Risky?
See More Headlines
Receive SYNH Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syneos Health and its competitors with MarketBeat's FREE daily newsletter.

SYNH Company Calendar

Last Earnings
11/03/2021
Today
2/07/2023
Next Earnings (Estimated)
2/16/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Commercial physical research
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SYNH
Employees
28,000
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$53.60
High Stock Price Forecast
$81.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+40.2%
Consensus Rating
Hold
Rating Score (0-4)
2.10
Research Coverage
10 Analysts

Profitability

Net Income
$234.83 million
Pretax Margin
7.22%

Debt

Sales & Book Value

Annual Sales
$5.21 billion
Cash Flow
$6.34 per share
Book Value
$32.91 per share

Miscellaneous

Free Float
102,554,000
Market Cap
$3.93 billion
Optionable
Optionable
Beta
1.65

Key Executives

  • Michelle KeefeMichelle Keefe
    Chief Executive Officer & Director
  • Michael BrooksMichael Brooks
    Chief Operating Officer
  • Jason Michael Meggs
    Chief Financial Officer
  • Larry A Pickett
    Chief Information & Digital Officer
  • Baba Shetty
    President-Technology & Data Solutions













SYNH Stock - Frequently Asked Questions

Should I buy or sell Syneos Health stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Syneos Health in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SYNH shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SYNH, but not buy additional shares or sell existing shares.
View SYNH analyst ratings
or view top-rated stocks.

What is Syneos Health's stock price forecast for 2023?

10 brokers have issued 1 year target prices for Syneos Health's shares. Their SYNH share price forecasts range from $25.00 to $81.00. On average, they predict the company's stock price to reach $53.60 in the next twelve months. This suggests a possible upside of 40.2% from the stock's current price.
View analysts price targets for SYNH
or view top-rated stocks among Wall Street analysts.

How have SYNH shares performed in 2023?

Syneos Health's stock was trading at $36.68 on January 1st, 2023. Since then, SYNH stock has increased by 4.2% and is now trading at $38.22.
View the best growth stocks for 2023 here
.

Are investors shorting Syneos Health?

Syneos Health saw a increase in short interest in January. As of January 15th, there was short interest totaling 7,250,000 shares, an increase of 19.6% from the December 31st total of 6,060,000 shares. Based on an average daily volume of 1,700,000 shares, the short-interest ratio is currently 4.3 days. Currently, 7.1% of the shares of the company are sold short.
View Syneos Health's Short Interest
.

When is Syneos Health's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 16th 2023.
View our SYNH earnings forecast
.

How were Syneos Health's earnings last quarter?

Syneos Health, Inc. (NASDAQ:SYNH) announced its earnings results on Wednesday, November, 3rd. The company reported $1.22 earnings per share for the quarter, beating the consensus estimate of $1.17 by $0.05. The firm had revenue of $1.35 billion for the quarter, compared to analysts' expectations of $1.34 billion. Syneos Health had a trailing twelve-month return on equity of 14.01% and a net margin of 5.31%. The firm's revenue for the quarter was up 22.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.93 EPS.

What guidance has Syneos Health issued on next quarter's earnings?

Syneos Health issued an update on its FY 2022 earnings guidance on Monday, January, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $5.30 billion-$5.36 billion, compared to the consensus revenue estimate of $5.32 billion.

What is Alistair Macdonald's approval rating as Syneos Health's CEO?

322 employees have rated Syneos Health Chief Executive Officer Alistair Macdonald on Glassdoor.com. Alistair Macdonald has an approval rating of 82% among the company's employees.

What other stocks do shareholders of Syneos Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syneos Health investors own include NVIDIA (NVDA), Pfizer (PFE), Block (SQ), Advanced Micro Devices (AMD), Boeing (BA), Alibaba Group (BABA), ICON Public (ICLR), Netflix (NFLX), AbbVie (ABBV) and Intel (INTC).

What is Syneos Health's stock symbol?

Syneos Health trades on the NASDAQ under the ticker symbol "SYNH."

Who are Syneos Health's major shareholders?

Syneos Health's stock is owned by many different institutional and retail investors. Top institutional shareholders include Assenagon Asset Management S.A. (1.03%), Reinhart Partners Inc. (0.40%), New York State Common Retirement Fund (0.30%), Allspring Global Investments Holdings LLC (0.28%), Natixis Advisors L.P. (0.26%) and Envestnet Asset Management Inc. (0.15%). Insiders that own company stock include Alistair Macdonald, Donna Hildebrand Kralowetz, International Corp/Ma Advent, Jason M Meggs, John L Maldonado, John M Dineen, Jonathan Olefson, Linda S Harty, Mark E Jagiela, Matthew E Monaghan, Matthew E Monaghan, Michael Lee Brooks, Michelle Keefe, Paul Colvin, Robert Parks, Thomas H Lee Advisors, Llc and Tom Allen.
View institutional ownership trends
.

How do I buy shares of Syneos Health?

Shares of SYNH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syneos Health's stock price today?

One share of SYNH stock can currently be purchased for approximately $38.22.

How much money does Syneos Health make?

Syneos Health (NASDAQ:SYNH) has a market capitalization of $3.93 billion and generates $5.21 billion in revenue each year. The company earns $234.83 million in net income (profit) each year or $2.75 on an earnings per share basis.

How many employees does Syneos Health have?

The company employs 28,000 workers across the globe.

How can I contact Syneos Health?

Syneos Health's mailing address is 1030 Sync Street, Morrisville NC, 27560. The official website for the company is www.syneoshealth.com. The company can be reached via phone at (919) 876-9300, via email at investor.relations@syneoshealth.com, or via fax at 919-876-9360.

This page (NASDAQ:SYNH) was last updated on 2/8/2023 by MarketBeat.com Staff